Home > Insider Trading > Filing (0001104659-10-062651)

Filing Details

Accession Number:: 0001104659-10-062651
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2010-12-14 17:34:40
Reporting Period:: 2010-12-10

Filing Date:: 2010-12-14
Accepted Time:: 2010-12-14 17:34:40
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1382911	Orexigen Therapeutics Inc.	OREX	Pharmaceutical Preparations (2834)	651178822

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1280249	Iii K Daniel Turner	C/O Orexigen Therapeutics, Inc 3344 N. Torrey Pines Court, Suite 200 La Jolla CA 92037		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2010-12-10	333,635	$0.00	865,077	No	4	S	Indirect	By Montreux Equity Partners II, SBIC, LP, Montreux Equity Partners III, SBIC, LP and related funds
Common Stock	Disposition	2010-12-13	266,365	$0.00	598,712	No	4	S	Indirect	By Montreux Equity Partners II, SBIC, LP, Montreux Equity Partners III, SBIC, LP and related funds

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By Montreux Equity Partners II, SBIC, LP, Montreux Equity Partners III, SBIC, LP and related funds
No	4	S	Indirect	By Montreux Equity Partners II, SBIC, LP, Montreux Equity Partners III, SBIC, LP and related funds

Footnotes

60,152 of the 333,635 share sold, were sold by Montreux Equity Partners II SBIC, L.P. 273,483 of the 333,635 shares sold, were sold by Montreux Equity Partners III SBIC, L.P.
The sale price for 273,483 of the 333,625 shares reported in this Form 4 was between the range of $8.84 per share and $8.55 per share, with the average sale price of $8.6131. The sale price for 60,152 of the 333,625 shares reported in this Form 4 was between the range of $8.80 per share and $8.60 per share, with the average sale price of $8.6825. Full information regarding the number of shares sold at each seperate price will be provided to the Commission staff upon request.
Of the total 865,077 total shares beneficially owned following the reported transaction, 439,204 shares are held by Montreux Equity Partners II SBIC, L.P. and 425,873 shares are held by Montreux Equity Partners III SBIC, L.P.
The reported securities are owned directly by Montreux Equity Partners II SBIC, L.P., ("MEP II") and Montreux Equity Partners III SBIC, L.P, ("MEP III"). The voting and disposition of the shares held by MEP II and MEP III are determined by Montreux Equity Management II SBIC, LLC, ("MEM II") and Montreux Equity Management III SBIC, LLC, ("MEM III"), respectively. Mr. Turner is a managing member of MEM II and MEM III. Mr. Turner disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
239,848 of the 266,365 share sold, were sold by Montreux Equity Partners II SBIC, L.P. 26,517 of the 266,365 shares sold, were sold by Montreux Equity Partners III SBIC, L.P.
The sale price for 26,517 of the 266,365 shares reported in this Form 4 was between the range of $8.71 per share and $8.60 per share, with an average sale price of $8.6452. The sale price for 239,848 of the 266,365 shares reported in this Form 4 was between the range of $8.68 per share and $8.60 per share, with an average sale price of $8.6094.Full information regarding the number of shares sold at each seperate price will be provided to the Commission staff upon request.
Of the total 598,712 total shares beneficially owned following the reported transaction, 199,356 shares are held by Montreux Equity Partners II SBIC, L.P. and 399,356 shares are held by Montreux Equity Partners III SBIC, L.P.